CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia

Bookmark and Share
Published: 1 Dec 2018
Views: 612
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

Dr Jordan Gauthier gives a press conference at ASH 2018 about the comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory chronic lymphocytic leukaemia (CLL).

Watch his interview with ecancer here.

Read the article about this work here.